NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is headquartered in Calabasas, California.
Metrics to compare | NTHI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNTHIPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.6x | −0.2x | −0.6x | |
PEG Ratio | 0.04 | 0.09 | 0.00 | |
Price/Book | −16.4x | 0.0x | 2.6x | |
Price / LTM Sales | 3,238.4x | 1.7x | 3.4x | |
Upside (Analyst Target) | - | 155.1% | 37.6% | |
Fair Value Upside | Unlock | 26.4% | 5.5% | Unlock |